Publications by authors named "Neda Al Rawashdh"
Article Synopsis
- This analysis evaluates the cost-effectiveness of cell-based vs. recombinant influenza vaccines in the US, focusing on adults aged 18-64 during the 2018-2019 flu season.
- A SEIR transmission model revealed that both vaccines significantly reduced influenza cases and related deaths, with the cell-based vaccine yielding better quality-adjusted life years (QALYs) and 36% lower costs, saving about $2.8 billion.
- The cell-based vaccine was found to be more cost-saving and effective overall, outperforming the recombinant vaccine and no vaccination across various payer perspectives.
Multiple myeloma (MM) accounts for 10% of hematologic cancers in the U.S.; however, incidence and mortality occur disproportionately between racial groups in real-world settings.
View Article and Find Full Text PDFBackground: Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a simulated trial comparing both regimens in stage IIIB/C-IV unresectable melanoma.
Research Design And Methods: Two trials with extractable OS curves for a T-VEC versus T-VEC + IPI comparison were identified. Outcomes were adjusted for heterogeneity in prognostic factors using a calculated adjustment factor.